Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
First Claim
Patent Images
1. A method of upregulating a function of and/or the expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one single stranded antisense oligonucleotide 19 to 21 nucleotides in length wherein said at least one oligonucleotide has at least 90% sequence identity to a reverse complement of a polynucleotide comprising 19 to 21 consecutive nucleotides within the natural antisense polynucleotide selected from the group consisting of nucleotides 1 to 1235 of SEQ ID SEQ ID NO;
6, 1 to 17,964 of SEQ ID NO;
7, 1 to 1 to 50,003 of SEQ ID SEQ ID NO;
8, 1 to 486 of SEQ ID NO;
9, 1 to 494 of SEQ ID NO;
10, 1 to 1992 of SEQ ID NO;
11, or 1 to 1767 of SEQ ID NO;
12 and wherein said antisense oligonucleotide specifically targets said natural antisense polynucleotide;
thereby upregulating a function of and/or the expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Pancreatic Developmental gene, in particular, by targeting natural antisense polynucleotides of a Pancreatic Developmental gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Pancreatic Developmental genes.
-
Citations
15 Claims
-
1. A method of upregulating a function of and/or the expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one single stranded antisense oligonucleotide 19 to 21 nucleotides in length wherein said at least one oligonucleotide has at least 90% sequence identity to a reverse complement of a polynucleotide comprising 19 to 21 consecutive nucleotides within the natural antisense polynucleotide selected from the group consisting of nucleotides 1 to 1235 of SEQ ID SEQ ID NO;
6, 1 to 17,964 of SEQ ID NO;
7, 1 to 1 to 50,003 of SEQ ID SEQ ID NO;
8, 1 to 486 of SEQ ID NO;
9, 1 to 494 of SEQ ID NO;
10, 1 to 1992 of SEQ ID NO;
11, or 1 to 1767 of SEQ ID NO;
12 and wherein said antisense oligonucleotide specifically targets said natural antisense polynucleotide;
thereby upregulating a function of and/or the expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.- View Dependent Claims (12)
-
2. A method of upregulating a function of and/or the expression of a Pancreatic Developmental gene polynucleotide selected from the group comprising SEQ ID NOS:
- 1-5 in patient cells or tissues in vivo or in vitro comprising;
contacting said cells or tissues with at least one single stranded antisense oligonucleotide 19 to 21 nucleotides in length wherein said at least one antisense oligonucleotide has at least 90% sequence identity to a corresponding 19 to 21 nucleotide region within a reverse complement of a natural antisense polynucleotide of a Pancreatic Developmental gene polynucleotide wherein said antisense oligonucleotide specifically targets said natural antisense polynucleotide;
thereby upregulating a function of and/or the expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.
- 1-5 in patient cells or tissues in vivo or in vitro comprising;
-
3. A method of upregulating a function of and/or the expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one modified single stranded antisense oligonucleotide of 19 to 21 nucleotides in length that specifically targets a complementary region of a natural antisense polynucleotide the Pancreatic Developmental gene;
thereby upregulating a function of and/or the expression of the Pancreatic Developmental gene in patient cells or tissues in vivo or in vitro.- View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11)
-
13. A method of upregulating a function of and/or the expression of a Pancreatic Developmental gene in mammalian cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 21 nucleotides in length, said at least one siRNA oligonucleotide being specific for a natural antisense polynucleotide of a Pancreatic Developmental gene, wherein said at least one siRNA oligonucleotide has at least 90% sequence complementarity to a sequence of at least about nineteen consecutive nucleic acids of the natural antisense polynucleotide; and
, upregulating a function of and/or the expression of a Pancreatic Developmental gene in mammalian cells or tissues in vivo or in vitro.- View Dependent Claims (14)
-
15. A method of upregulating a function of and/or the expression of a Pancreatic Developmental gene in mammalian cells or tissues in vitro comprising:
contacting said cells or tissues with at least one single stranded modified antisense oligonucleotide of about 19 to 21 nucleotides in length specific for a natural antisense polynucleotide of a Pancreatic Developmental gene wherein said at least one antisense oligonucleotide has at least 90% sequence identity to a 19 to 21 consecutive nucleotide region of the group consisting of SEQ ID NOS;
1 to 5 or polynucleotides transcribed from the Pancreatic Developmental gene; and
, upregulating the function and/or expression of the Pancreatic Developmental gene in mammalian cells or tissues in vitro.
Specification